Page 1

prothena Prothena Reports Second Quarter 2021 Financial Results and Business Highlights August 5 , 2021 • Net cash provided by operating and investing activities was $ 36.6 million in the second quarter and $ 2.9 million for the first six months of 2021 ; quarter - end cash and restricted cash position of $ 402.5 million ( includes $ 60 million payment from Roche ) provides additional funding to continue advancing R & D pipeline • Announced multiple strategic collaborations delivering milestones in 2021 and potentially beyond • Presented preclinical data at AAIC for two product candidates being developed for Alzheimer's disease , PRX012 next - generation anti - Aß antibody and dual Aß - tau vaccine DUBLIN , Ireland , Aug. 05 , 2021 ( GLOBE NEWSWIRE ) Prothena Corporation plc ( NASDAQ : PRTA ) , a late - stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise , today reported financial results for the second quarter and first six months of 2021. In addition , the Company provided business highlights and updated 2021 financial guidance . " We continued to make significant progress advancing our robust portfolio with our confirmatory Phase 3 AFFIRM - AL trial of birtamimab in AL amyloidosis and new preclinical data presented at AAIC that highlighted two of our potentially best - in - class Alzheimer's programs , PRX012 , a high - potency anti - Aß antibody designed for subcutaneous administration to enhance patient access and compliance , and our dual Aß - tau vaccine for the prevention and treatment of Alzheimer's , " said Gene Kinney , Ph.D. , President and Chief Executive Officer of Prothena . " Additionally , multiple strategic collaborations delivered milestones with a combined $ 200 million in partner payments this year from Roche , Bristol Myers Squibb and Novo Nordisk . Progress across our portfolio continues to validate our scientific platform and capital earned through our strategic partnerships helps to advance our robust pipeline through key milestones . As we continue to work towards our mission to bring novel therapies to patients in need of new treatment options , we welcomed Sanjiv Patel to our board , who brings significant industry experience to advise Prothena as we transition to a fully integrated research , development and commercial biotechnology company . " Second Quarter and Recent Business Highlights : Multiple milestones from strategic collaborations • $ 60 million milestone from Roche for prasinezumab received in 2Q 2021 • $ 80 million milestone from Bristol Myers Squibb for PRX005 expected in 3Q 2021 • Up to $ 1.23 billion from Novo Nordisk for ATTR amyloidosis , including $ 60 million upfront payment received in 3Q 2021 and $ 40 million milestone expected 1H 2022 Birtamimab , a potential treatment for AL amyloidosis , is a humanized monoclonal antibody designed to directly neutralize soluble toxic aggregates and promote clearance of amyloid that causes organ dysfunction and failure • Confirmatory Phase 3 AFFIRM - AL study of birtamimab in Mayo Stage IV patients with AL amyloidosis ( NCT # 04973137 ) Prasinezumab , a potential treatment for Parkinson's disease , is a humanized monoclonal antibody designed to target a key epitope within the C - terminus of alpha - synuclein and is the focus of the worldwide collaboration with Roche • Earned $ 60 million clinical milestone payment upon dosing of the first patient in the global Phase 2b PADOVA study for prasinezumab , which was announced in May 2021 ( NCT # 04777331 ) PRX004 , a potential treatment for ATTR amyloidosis , is a humanized monoclonal antibody designed to deplete the pathogenic , non - native forms of the TTR protein , and is being developed by Novo Nordisk for the treatment of ATTR cardiomyopathy • Announced Novo Nordisk acquisition of ATTR amyloidosis business ; Prothena is eligible to receive development and sales milestones up to $ 1.23 billion o Includes $ 100 million in upfront and near - term milestone payments ( received $ 60 million upfront in 3Q 2021 and potential for $ 40 million upon initiation of Phase 2 study in ATTR cardiomyopathy patients ) PRX005 , a potential treatment for Alzheimer's disease ( AD ) , is an investigational antibody that specifically targets a key epitope within the microtubule binding region ( MTBR ) of tau , a protein implicated in diseases including AD , frontotemporal dementia ( FTD ) , progressive supranuclear palsy ( PSP ) , chronic traumatic encephalopathy ( CTE ) and other tauopathies . PRX005 is part of the global neuroscience research and development collaboration with Bristol Myers Squibb • Bristol Myers Squibb exercised its option under the global neuroscience research and development collaboration and entered into an exclusive U.S. license for PRX005 . Prothena is expected to receive $ 80 million from Bristol Myers Squibb